Form 4: Nurix Therapeutics Director Edward C. Saltzman Granted Stock Options

Director Edward C. Saltzman of Nurix Therapeutics, Inc. was granted stock options to purchase 25,000 shares of common stock on May 20, 2024.

Summary

• On May 20, 2024, Edward C. Saltzman, a director of Nurix Therapeutics, Inc., was granted stock options.
• The options allow him to purchase 25,000 shares of the company's common stock at an exercise price of $16.19 per share.
• The stock options vest fully on the earlier of the next annual meeting of the Issuer's stockholders or May 20, 2025, contingent upon Saltzman's continued service to the Issuer.
• The options expire on May 19, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating a stable and incentivized management structure. The sentiment is neutral to slightly positive.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service to the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the stock options.

Industry Context

Granting stock options to directors is a common practice in the biotechnology industry to incentivize performance and align interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their directors and key employees.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The granting of stock options can positively impact shareholders by aligning the director's interests with the company's long-term success.
• Employees may view this as a positive sign of investment in leadership.

Key Dates